Why Invest in Linker Sciences?

• Disruptive Platform Technology
  Linker Sciences combines high-resolution mass spectrometry, advanced laboratory automation, and AI-driven data analytics to enable drug discovery efforts from underexplored natural sources of North America. Our platform allows high-throughput identification and validation of bioactive compounds with speed, sensitivity, and reproducibility compared to conventional drug discovery methods. We, at Linker Sciences, are developing proprietary workflows and system-level integration that combine established technologies in a novel and protected configuration.
  
  

• Dual Strategy: Platform + Pipeline
  Our disease-agnostic core technology can be applied across diverse therapeutic areas with the flexibility to pursue high-value indications through strategic partnerships and investor alignment.
  
  

• Massive Market Opportunity
  Early discovery represents a $50B+ annual spend globally, yet suffers from long timelines, high costs, and ~90% attrition rates. Our Spectra Decoding Platform (SDP) addresses these inefficiencies by leveraging our natural, biological, and synthetic libraries to drive faster R&D and enable strategic collaborations with pharma and biotech partners.
  
  

• Defensible Technology
  Our proprietary experimental protocols and AI analytics provide a clear technical moat. Early benchmarking reveals a massive, drug-like chemical space within natural products that is inaccessible to conventional drug discovery workflows.
  
  

• Early Execution and Momentum
  We have developed a prototype discovery platform, secured access to curated compound libraries and data pipelines, and are in active discussions with pharmaceutical advisors.
  
  

• Strategic Fit for Mission-Aligned Investors
  We are seeking mission-aligned angel investors and early backers interested in scalable entry into therapeutics R&D, with potential upside from both platform partnerships and future IND-stage compound licensing.
  
  

• Capital Raising Status
  We are raising pre-seed capital to advance platform validation, expand our core team, and initiate pilot discovery projects.

• Non-Dilutive Funding Strategy

We are in active discussions with the SBIR program office to pursue federal non-dilutive funding opportunities. These efforts run in parallel with our equity fundraising.

• Let’s Talk
  Reach us directly at info@LinkerSciences.com to discuss the opportunity, review our pitch deck, or arrange a call.